FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992118957> ?p ?o ?g. }

• W1992118957 endingPage "3877" @default.
• W1992118957 startingPage "3869" @default.
• W1992118957 abstract "Salivary gland tumors (SGT) are a group of highly heterogeneous head and neck malignancies with widely varied clinical outcomes and no standard effective treatments. The CRTC1–MAML2 fusion oncogene, encoded by a recurring chromosomal translocation t(11;19)(q14-21;p12-13), is a frequent genetic alteration found in >50% of mucoepidermoid carcinomas (MEC), the most common malignant SGT. In this study, we aimed to define the role of the CRTC1–MAML2 oncogene in the maintenance of MEC tumor growth and to investigate critical downstream target genes and pathways for therapeutic targeting of MEC. By performing gene expression analyses and functional studies via RNA interference and pharmacological modulation, we determined the importance of the CRTC1–MAML2 fusion gene and its downstream AREG–EGFR signaling in human MEC cancer cell growth and survival in vitro and in vivo using human MEC xenograft models. We found that CRTC1–MAML2 fusion oncogene was required for the growth and survival of fusion-positive human MEC cancer cells in vitro and in vivo. The CRTC1–MAML2 oncoprotein induced the upregulation of the epidermal growth factor receptor (EGFR) ligand Amphiregulin (AREG) by co-activating the transcription factor CREB, and AREG subsequently activated EGFR signaling in an autocrine manner that promoted MEC cell growth and survival. Importantly, CRTC1–MAML2-positive MEC cells were highly sensitive to EGFR signaling inhibition. Therefore, our study revealed that aberrantly activated AREG–EGFR signaling is required for CRTC1–MAML2-positive MEC cell growth and survival, suggesting that EGFR-targeted therapies will benefit patients with advanced, unresectable CRTC1–MAML2-positive MEC." @default.
• W1992118957 created "2016-06-24" @default.
• W1992118957 creator A5001137299 @default.
• W1992118957 creator A5005862221 @default.
• W1992118957 creator A5006086518 @default.
• W1992118957 creator A5008270498 @default.
• W1992118957 creator A5013121236 @default.
• W1992118957 creator A5021700943 @default.
• W1992118957 creator A5038528880 @default.
• W1992118957 creator A5039503690 @default.
• W1992118957 creator A5060192502 @default.
• W1992118957 creator A5071233294 @default.
• W1992118957 creator A5072610753 @default.
• W1992118957 creator A5077165626 @default.
• W1992118957 creator A5077837608 @default.
• W1992118957 creator A5089101408 @default.
• W1992118957 date "2013-08-26" @default.
• W1992118957 modified "2023-09-29" @default.
• W1992118957 title "Aberrantly activated AREG–EGFR signaling is required for the growth and survival of CRTC1–MAML2 fusion-positive mucoepidermoid carcinoma cells" @default.
• W1992118957 cites W1508234976 @default.
• W1992118957 cites W1948759062 @default.
• W1992118957 cites W1964297775 @default.
• W1992118957 cites W1971542014 @default.
• W1992118957 cites W1973548313 @default.
• W1992118957 cites W1974202442 @default.
• W1992118957 cites W1981390696 @default.
• W1992118957 cites W1981917109 @default.
• W1992118957 cites W2000145238 @default.
• W1992118957 cites W2009661936 @default.
• W1992118957 cites W2011498834 @default.
• W1992118957 cites W2013579158 @default.
• W1992118957 cites W2013997037 @default.
• W1992118957 cites W2018406388 @default.
• W1992118957 cites W2019010829 @default.
• W1992118957 cites W2029210470 @default.
• W1992118957 cites W2034758824 @default.
• W1992118957 cites W2035984881 @default.
• W1992118957 cites W2044183621 @default.
• W1992118957 cites W2060525726 @default.
• W1992118957 cites W2062838157 @default.
• W1992118957 cites W2075451702 @default.
• W1992118957 cites W2093877599 @default.
• W1992118957 cites W2112650802 @default.
• W1992118957 cites W2113933637 @default.
• W1992118957 cites W2129307197 @default.
• W1992118957 cites W2132431231 @default.
• W1992118957 cites W2138930548 @default.
• W1992118957 cites W2152452482 @default.
• W1992118957 cites W2158421326 @default.
• W1992118957 cites W2184203459 @default.
• W1992118957 cites W2329958542 @default.
• W1992118957 doi "https://doi.org/10.1038/onc.2013.348" @default.
• W1992118957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23975434" @default.
• W1992118957 hasPublicationYear "2013" @default.
• W1992118957 type Work @default.
• W1992118957 sameAs 1992118957 @default.
• W1992118957 citedByCount "74" @default.
• W1992118957 countsByYear W19921189572014 @default.
• W1992118957 countsByYear W19921189572015 @default.
• W1992118957 countsByYear W19921189572016 @default.
• W1992118957 countsByYear W19921189572017 @default.
• W1992118957 countsByYear W19921189572018 @default.
• W1992118957 countsByYear W19921189572019 @default.
• W1992118957 countsByYear W19921189572020 @default.
• W1992118957 countsByYear W19921189572021 @default.
• W1992118957 countsByYear W19921189572022 @default.
• W1992118957 countsByYear W19921189572023 @default.
• W1992118957 crossrefType "journal-article" @default.
• W1992118957 hasAuthorship W1992118957A5001137299 @default.
• W1992118957 hasAuthorship W1992118957A5005862221 @default.
• W1992118957 hasAuthorship W1992118957A5006086518 @default.
• W1992118957 hasAuthorship W1992118957A5008270498 @default.
• W1992118957 hasAuthorship W1992118957A5013121236 @default.
• W1992118957 hasAuthorship W1992118957A5021700943 @default.
• W1992118957 hasAuthorship W1992118957A5038528880 @default.
• W1992118957 hasAuthorship W1992118957A5039503690 @default.
• W1992118957 hasAuthorship W1992118957A5060192502 @default.
• W1992118957 hasAuthorship W1992118957A5071233294 @default.
• W1992118957 hasAuthorship W1992118957A5072610753 @default.
• W1992118957 hasAuthorship W1992118957A5077165626 @default.
• W1992118957 hasAuthorship W1992118957A5077837608 @default.
• W1992118957 hasAuthorship W1992118957A5089101408 @default.
• W1992118957 hasBestOaLocation W19921189571 @default.
• W1992118957 hasConcept C104317684 @default.
• W1992118957 hasConcept C121608353 @default.
• W1992118957 hasConcept C128240485 @default.
• W1992118957 hasConcept C170493617 @default.
• W1992118957 hasConcept C2779438470 @default.
• W1992118957 hasConcept C2780806702 @default.
• W1992118957 hasConcept C2781018059 @default.
• W1992118957 hasConcept C29537977 @default.
• W1992118957 hasConcept C502942594 @default.
• W1992118957 hasConcept C54355233 @default.
• W1992118957 hasConcept C62112901 @default.
• W1992118957 hasConcept C86339819 @default.
• W1992118957 hasConcept C86803240 @default.
• W1992118957 hasConceptScore W1992118957C104317684 @default.
• W1992118957 hasConceptScore W1992118957C121608353 @default.

• next